New combo therapy targets hard-to-treat brain metastasis in lung cancer patients
NCT ID NCT07398599
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a higher dose of a targeted therapy (EGFR-TKI) combined with two other drugs for people with advanced lung cancer that has spread to the lining of the brain and worsened on standard treatment. About 30 participants will receive the triple combination to see if it shrinks the brain lining tumors and to track side effects. The goal is to control the disease, not cure it, as ongoing treatment is needed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEPTOMENINGEAL METASTASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second Affiliated Hospital of Nanchang University
RECRUITINGNanchang, Jiangxi, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can removing the primary tumor extend control in EGFR-Mutant lung cancer?
- Spinal injection of dual immunotherapy plus chemotherapy targets cancer spread to brain lining
- Spinal fluid injection of Dual-Target antibody and chemotherapy shows promise for deadly cancer complication
- Smartwatch could alert doctors to brain cancer complications before they worsen
- Triple therapy targets tough brain metastases in lung cancer
- New hope for lung cancer patients with brain-spread disease